Lieberman A N, Foo S H, Ransohoff J, Wise A, George A, Gordon W, Walker R
Neurosurgery. 1982 Apr;10(4):450-3. doi: 10.1227/00006123-198204000-00006.
Eight of 57 patients (14%) with malignant astrocytomas lived at least 2 years. The mean survival time was 143 weeks (range, 104 to 250 weeks). All of the patients were treated with operation, radiation, and chemotherapy. Four of the 8 patients died because of tumor recurrence, 1 died from a second primary tumor, 2 died of cases unrelated to the tumor, and 1 is still alive. Diffuse cortical dysfunction associated with cortical atrophy that could not be related to tumor regrowth and was not explained by focal deficits, psychotic of depressive thought disorders, metabolic or endocrine abnormalities, or hydrocephalus developed in the 3 longest-surviving patients. The diffuse dysfunction was initially apparent only through psychometric testing, but eventually became so disabling as to result in 2 of the 3 patients retiring from work. Although small, but gratifying, gains have been made in the treatment of patients with malignant brain tumors, accompanying these gains have been problems of a magnitude that is only now beginning to be appreciated.
57例恶性星形细胞瘤患者中有8例(14%)存活至少2年。平均生存时间为143周(范围为104至250周)。所有患者均接受了手术、放疗和化疗。8例患者中有4例因肿瘤复发死亡,1例死于第二原发性肿瘤,2例死于与肿瘤无关的情况,1例仍存活。3例存活时间最长的患者出现了与皮质萎缩相关的弥漫性皮质功能障碍,这种障碍与肿瘤再生长无关,也不能用局灶性缺损、精神病性或抑郁性思维障碍、代谢或内分泌异常或脑积水来解释。这种弥漫性功能障碍最初仅通过心理测试才明显,但最终变得如此致残,以至于3例患者中有2例退休。虽然在恶性脑肿瘤患者的治疗方面取得了虽小但令人满意的进展,但伴随着这些进展出现了一些问题,其严重程度直到现在才开始被认识到。